Monte Rosa Therapeutics: Mrt-8102, a Nek7-Directed Mgd Targeting Diseases Driven by Il-1Β & Nlrp3 Inflammasome, on Track for Ind Filing in H1 2025
Monte Rosa Therapeutics: Mrt-8102,一種針對由Il-1β和Nlrp3炎症小體驅動疾病的Nek7導向Mgd,計劃於2025年上半年提交IND申請
Monte Rosa Therapeutics: Mrt-8102, a Nek7-Directed Mgd Targeting Diseases Driven by Il-1Β & Nlrp3 Inflammasome, on Track for Ind Filing in H1 2025
Monte Rosa Therapeutics: Mrt-8102,一種針對由Il-1β和Nlrp3炎症小體驅動疾病的Nek7導向Mgd,計劃於2025年上半年提交IND申請
譯文內容由第三人軟體翻譯。
評論(0)
請選擇舉報原因